Lansoprazole: an alternative method of administration of a capsule dosage formulation

Clin Ther. 1995 May-Jun;17(3):441-7. doi: 10.1016/0149-2918(95)80109-x.

Abstract

A single-dose, open-label, randomized, fasting, two-period, crossover bioavailability study was conducted in 24 healthy adult men to assess an alternative method of administration of lansoprazole capsules. Half of the subjects received regimen A (contents from a 30-mg capsule placed in a tablespoonful of applesauce), and the other half received regimen B (an intact 30-mg capsule) during period 1 of the crossover study. The regimens were reversed during the second period 1 week later. Blood samples were obtained over 12 hours and pharmacokinetic parameters were determined. Mean time elapsed to peak concentration (Tmax) was less than 2 hours for each regimen. The ratio (regimen A:regimen B) of peak concentration (Cmax) means and area under the curve (AUC)0-infinity means were 0.889 and 0.944, respectively. (AUC0-infinity is the sum of AUC0-t and AUCt-infinity, where AUC0-t is the area under the plasma concentration-time curve from time 0 to the time of the last measurable or nonzero concentration as computed by using the trapezoidal rule, and AUCt-infinity is computed as the last nonzero concentration divided by the terminal phase rate constant.) No statistically significant differences (P < or = 0.05) in Tmax, Cmax, and AUC0-infinity were detected between regimens. These data indicate similar bioavailabilities between the two regimens. Lansoprazole granules contained in a standard capsule dosage formulation may be removed and placed directly into applesauce and administered to appropriate patients.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Anti-Ulcer Agents / administration & dosage*
  • Anti-Ulcer Agents / adverse effects
  • Anti-Ulcer Agents / pharmacokinetics
  • Biological Availability
  • Capsules
  • Chromatography, High Pressure Liquid
  • Cross-Over Studies
  • Female
  • Humans
  • Lansoprazole
  • Male
  • Middle Aged
  • Omeprazole / administration & dosage
  • Omeprazole / adverse effects
  • Omeprazole / analogs & derivatives*
  • Omeprazole / pharmacokinetics

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Capsules
  • Lansoprazole
  • Omeprazole